Fig. 2
Molecular subclassification of SCLC. SCLC subclassification discriminates between NE subtypes which are represented by ASCL1- or NEUROD1-driven tumors and non-NE subtypes characterized by POU2F3 or inflamed expression patterns. Distinct expression profiles show potential vulnerabilities of each SCLC subtype. Created with BioRender.com. TP53—Tumor protein 53; RB1 - Retinoblastoma 1; NE - neuroendocrine; PNEC - Pulmonary NE cells; ASCL1 - Achaete-scute homologue 1; NEUROD1 - Neurogenic differentiation factor 1; POU2F3 - POU class 2 homeobox 3; YAP1 - Yes-associated protein 1, QN - Quadruple negative, BCL2 - B-cell lymphoma 2, DLL3 - Delta-like protein 3, CHGA – Chromogranin A, EZH2 - Enhancer of zeste homologue 2, SOX2 - SRY-box transcription factor 2, CDH1 – E-cadherin, TTF-1 - Homeobox protein Nkx2.1, LSD1 - Lysine demethylase 1A, RET - Ret proto-oncogene, AURKA – Aurora kinase A, MYC – MYC proto-oncogene, NCAM1 - Neural cell adhesion molecule 1, NFIB - Nuclear factor 1 B, HES6 - Hairy and enhancer of split 6, ANTXR1 - Anthrax toxin receptor 1, INSM1 - Insulinoma-associated protein 1, ASCL2 - Achaete-scute homologue 2, IGF-1R - Insulin-growth factor receptor 1, SOX9 - SRY-box transcription factor 9, CHAT - Choline O-acetyltransferase, ATM - ATM serine/threonine kinase, TAZ - Homologue to YAP1, PLK - Polo-like kinase, PD-L1 - Programmed death-ligand 1, mTOR – Rapamycin, CDK4/6 - Cyclin-dependent kinases 4/6